These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 11025182

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.
    Spangler SK, Jacobs MR, Appelbaum PC.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():23-7. PubMed ID: 9222066
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro activities of antibiotic combinations against clincal isolates of Pseudomonas aeruginosa.
    Chen YH, Peng CF, Lu PL, Tsai JJ, Chen TP.
    Kaohsiung J Med Sci; 2004 Jun; 20(6):261-7. PubMed ID: 15253466
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Carbapenemase-producing Pseudomonas aeruginosa in UK.
    Woodford N, Palepou MF, Babini GS, Bates J, Livermore DM.
    Lancet; 1998 Aug 15; 352(9127):546-7. PubMed ID: 9716067
    [No Abstract] [Full Text] [Related]

  • 13. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
    Chan E, Zhou S, Srikumar S, Duan W.
    Pharm Res; 2006 Apr 15; 23(4):729-41. PubMed ID: 16554956
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro activity of piperacillin/tazobactam against 615 Pseudomonas aeruginosa strains isolated in intensive care units.
    Bonfiglio G, Laksai Y, Franceschini N, Perilli M, Segatore B, Bianchi C, Stefani S, Amicosante G, Nicoletti G.
    Chemotherapy; 1998 Apr 15; 44(5):305-12. PubMed ID: 9732144
    [Abstract] [Full Text] [Related]

  • 17. [In vitro antibacterial activity of piperacillin-tazobactam in combination with netilmicin or amikacin against Enterobacteriaceae resistant to amoxicillin].
    Duez JM, Siebor E, Pechinot A, Cordin X, Chamard-Neuwirth C, Kazmierczak A.
    Pathol Biol (Paris); 1995 Mar 15; 43(3):208-14. PubMed ID: 7675548
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers.
    Strenkoski-Nix LC, Forrest A, Schentag JJ, Nix DE.
    J Clin Pharmacol; 1998 Nov 15; 38(11):1063-71. PubMed ID: 9824789
    [Abstract] [Full Text] [Related]

  • 19. Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates.
    Jung R, Husain M, Choi MK, Fish DN.
    Antimicrob Agents Chemother; 2004 Mar 15; 48(3):1055-7. PubMed ID: 14982809
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.